Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysis.
Por:
Garcia Quesada M, Peterson ME, Bennett JC, Hayford K, Zeger SL, Yang Y, Hetrich MK, Feikin DR, Cohen AL, von Gottberg A, van der Linden M, van Sorge NM, de Oliveira LH, de Miguel S, Yildirim I, Vestrheim DF, Verani JR, Varon E, Valentiner-Branth P, Tzanakaki G, Sinkovec Zorko N, Setchanova LP, Serhan F, Scott KJ, Scott JA, Savulescu C, Savrasova L, Reyburn R, Oishi K, Nuorti JP, Napoli D, Mwenda JM, Munoz-Almagro C, Morfeldt E, McMahon K, McGeer A, Mad'arová L, Mackenzie GA, Eugenia León M, Ladhani SN, Kristinsson KG, Kozakova J, Kleynhans J, Klein NP, Kellner JD, Jayasinghe S, Ho PL, Hilty M, Harker-Jones MA, Hammitt LL, Grgic-Vitek M, Gilkison C, Gierke R, French N, Diawara I, Desmet S, De Wals P, Dalby T, Dagan R, Corcoran M, Colzani E, Chanto Chacón G, Castilla J, Camilli R, Ang M, Ampofo K, Almeida SCG, Alarcon P, O'Brien KL and Deloria Knoll M
Publicada:
1 abr 2025
Ahead of Print:
17 dic 2024
Resumen:
BACKGROUND: Widespread use of pneumococcal conjugate vaccines (PCVs) has reduced vaccine-type invasive pneumococcal disease (IPD). We describe the serotype distribution of IPD after extensive use of ten-valent PCV (PCV10; Synflorix, GSK) and 13-valent PCV (PCV13; Prevenar 13, Pfizer) globally. METHODS: IPD data were obtained from surveillance sites participating in the WHO-commissioned Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project that exclusively used PCV10 or PCV13 (hereafter PCV10 and PCV13 sites, respectively) in their national immunisation programmes and had primary series uptake of at least 70%. Serotype distribution was estimated for IPD cases occurring 5 years or more after PCV10 or PCV13 introduction (ie, the mature period when the serotype distribution had stabilised) using multinomial Dirichlet regression, stratified by PCV product and age group (<5 years, 5-17 years, 18-49 years, and =50 years). FINDINGS: The analysis included cases occurring primarily between 2015 and 2018 from 42 PCV13 sites (63 362 cases) and 12 PCV10 sites (6806 cases) in 41 countries. Sites were mostly high income (36 [67%] of 54) and used three-dose or four-dose booster schedules (44 [81%]). At PCV10 sites, PCV10 serotypes caused 10·0% (95% CI 6·3-12·9) of IPD cases in children younger than 5 years and 15·5% (13·4-19·3) of cases in adults aged 50 years or older, while PCV13 serotypes caused 52·1% (49·2-65·4) and 45·6% (40·0-50·0), respectively. At PCV13 sites, PCV13 serotypes caused 26·4% (21·3-30·0) of IPD cases in children younger than 5 years and 29·5% (27·5-33·0) of cases in adults aged 50 years or older. The leading serotype at PCV10 sites was 19A in children younger than 5 years (30·6% [95% CI 18·2-43·1]) and adults aged 50 years or older (14·8% [11·9-17·8]). Serotype 3 was a top-ranked serotype, causing about 9% of cases in children younger than 5 years and 14% in adults aged 50 years or older at both PCV10 and PCV13 sites. Across all age and PCV10 or PCV13 strata, the proportion of IPD targeted by higher-valency PCVs beyond PCV13 was 4·1-9·7% for PCV15, 13·5-36·0% for PCV20, 29·9-53·8% for PCV21, 15·6-42·0% for PCV24, and 31·5-50·1% for PCV25. All top-ten ranked non-PCV13 serotypes are included in at least one higher-valency PCV. INTERPRETATION: The proportion of IPD due to serotypes included in PCVs in use was low in mature PCV10 and PCV13 settings. Serotype distribution differed between PCV10 and PCV13 sites and age groups. Higher-valency PCVs target most remaining IPD and are expected to extend impact. FUNDING: Bill & Melinda Gates Foundation as part of the WHO Pneumococcal Vaccines Technical Coordination Project.
Filiaciones:
Garcia Quesada M:
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Peterson ME:
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Bennett JC:
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Hayford K:
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Zeger SL:
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Yang Y:
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Hetrich MK:
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Feikin DR:
WHO, Geneva, Switzerland
Cohen AL:
WHO, Geneva, Switzerland
von Gottberg A:
Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa
School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
van der Linden M:
Reference Laboratory for Streptococci, Department of Medical Microbiology, University Hospital RWTH Aachen, Aachen, Germany
van Sorge NM:
Medical Microbiology and Infection Prevention, Netherlands Reference Laboratory for Bacterial Meningitis, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
de Oliveira LH:
Pan American Health Organization, WHO, Washington, DC, USA
de Miguel S:
CIBER de Enfermedades Respiratorias, Madrid, Spain
Epidemiology Department, Dirección General de Salud Pública, Madrid, Spain
Yildirim I:
Department of Pediatrics, Yale New Haven Children's Hospital, New Haven, CT, USA
Vestrheim DF:
Department of Public Health, Ministry of Health and Care Services, Oslo, Norway
Verani JR:
Division of Global Health Protection, Center for Global Health, Centers for Disease Control and Prevention, Nairobi, Kenya
Division of Bacterial Diseases, National Center for Immunizations and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA, USA
Varon E:
National Reference Centre for Pneumococci, Data Research Department, Intercommunal Hospital of Créteil, Créteil, France
Valentiner-Branth P:
Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark
Tzanakaki G:
National Meningitis Reference Laboratory, Department of Public Health Policy, School of Public Health, University of West Attica, Athens, Greece
Sinkovec Zorko N:
Communicable Diseases Centre, National Institute of Public Health, Ljubljana, Slovenia
Setchanova LP:
University Multiprofile Hospital for Active Treatment Saint Ivan Rilski, Clinical Microbiology Laboratory, Sofia, Bulgaria
Serhan F:
WHO, Geneva, Switzerland
Scott KJ:
Bacterial Respiratory Infection Service, Scottish Microbiology Reference Laboratory, NHS Greater Glasgow and Clyde, Glasgow, UK
Scott JA:
Epidemiology and Demography Department, KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Coast, Kilifi, Kenya
Savulescu C:
Epidemiology Department, Epiconcept, Paris, France
Savrasova L:
Institute of Public Health, Riga Stradinš University, Riga, Latvia
Reyburn R:
Murdoch Children's Research Institute, Parkville, VIC, Australia
Oishi K:
Toyama Institute of Health, Toyama, Japan
Nuorti JP:
Department of Health Security, Finnish Institute for Health and Welfare, Helsinki, Finland
Health Sciences Unit, Faculty of Social Sciences, Tampere University, Tampere, Finland
Napoli D:
Clinical Bacteriology Service, Department of Bacteriology, National Institute for Infectious Diseases (INEI-ANLIS) "Dr Carlos G Malbrán", Buenos Aires, Argentina
Mwenda JM:
WHO Regional Office for Africa, Brazzaville, Republic of the Congo
Munoz-Almagro C:
Medicine Department, International University of Catalunya, Barcelona, Spain
Molecular Microbiology Department, Hospital Sant Joan de Déu Research Institute, Barcelona, Spain
CIBER Epidemiología y Salud Pública, Madrid, Spain
Morfeldt E:
Department of Microbiology Public Health Agency of Sweden, Solna, Sweden
McMahon K:
Centre for Disease Control, Department of Health and Community Services, Darwin, NT, Australia
McGeer A:
Toronto Invasive Bacterial Diseases Network and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
Mad'arová L:
National Reference Centre for Pneumococcal and Haemophilus Diseases, Regional Authority of Public Health, Banská Bystrica, Slovakia
Mackenzie GA:
New Vaccines Group, Murdoch Children's Research Institute, Parkville, VIC, Australia
Department of Paediatrics, University of Melbourne, Parkville, VIC, Australia
Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK
Medical Research Council Unit The Gambia at London School of Hygiene & Tropical Medicine, Banjul, The Gambia
Eugenia León M:
Central Laboratory of Public Health, Asunción, Paraguay
Ladhani SN:
Immunisation and Countermeasures Division, UK Health Security Agency, London, UK
Kristinsson KG:
Department of Clinical Microbiology, Landspitali-The National University Hospital, Reykjavik, Iceland
Kozakova J:
National Institute of Public Health, Prague, Czech Republic
Kleynhans J:
Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa
School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Klein NP:
Vaccine Study Center, Kaiser Permanente, Oakland, CA, USA
Kellner JD:
Department of Pediatrics, University of Calgary and Alberta Health Services, Calgary, AB, Canada
Jayasinghe S:
National Centre for Immunisation Research and Surveillance and Discipline of Child and Adolescent Health, Children's Hospital Westmead Clinical School, Faculty of Medicine and Health, University of Sydney, Westmead, NSW, Australia
Ho PL:
Department of Microbiology and Carol Yu Centre for Infection, Queen Mary Hospital, The University of Hong Kong, Hong Kong Special Administrative Region, China
Hilty M:
Swiss National Reference Centre for Invasive Pneumococci, Institute for Infectious Diseases, University of Bern, Bern, Switzerland
Harker-Jones MA:
Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, US Centers for Disease Control and Prevention, Anchorage, AK, USA
Hammitt LL:
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Epidemiology and Demography Department, KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Coast, Kilifi, Kenya
Grgic-Vitek M:
Communicable Diseases Centre, National Institute of Public Health, Ljubljana, Slovenia
Gilkison C:
Epidemiology Team, Institute of Environmental Science and Research, Porirua, New Zealand
Gierke R:
Division of Bacterial Diseases, National Center for Immunizations and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA, USA
French N:
Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK
Malawi Liverpool Wellcome Programme, Blantyre, Malawi
Diawara I:
Infectious Diseases Research Unit, Mohammed VI Center for Research & Innovation (CM6RI), Rabat, Morocco
Mohammed VI University of Sciences and Health, Mohammed VI Higher Institute of Biosciences and Biotechnologies (UM6SS), Casablanca, Morocco
Desmet S:
Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium
National Reference Centre for Streptococcus Pneumoniae, University Hospitals Leuven, Leuven, Belgium
De Wals P:
Department of Social and Preventive Medicine, Laval University, Québec, QC, Canada
Dalby T:
Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark
Dagan R:
The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
Corcoran M:
Irish Meningitis and Sepsis Reference Laboratory, Children's Health Ireland at Temple Street, Dublin, Ireland
Royal College of Surgeons in Ireland, Dublin, Ireland
Colzani E:
European Centre for Disease Prevention and Control, Solna, Sweden
Chanto Chacón G:
Costa Rican Institute for Research and Teaching in Nutrition and Health, Tres Ríos, Costa Rica
Castilla J:
CIBER Epidemiología y Salud Pública, Madrid, Spain
Public Health Institute of Navarre, Pamplona, Spain
Navarre Institute for Health Research, Pamplona, Spain
Camilli R:
Department of Infectious Diseases, Italian National Institute of Health, Rome, Italy
Ang M:
National Public Health Laboratory, National Centre for Infectious Diseases, Singapore
Ampofo K:
Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Utah Health Sciences Center, Salt Lake City, UT, USA
Almeida SCG:
National Laboratory for Meningitis and Pneumococcal Infections, Center of Bacteriology, Institute Adolfo Lutz, São Paulo, Brazil
Alarcon P:
Instituto de Salud Pública de Chile, Santiago, Chile
O'Brien KL:
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
WHO, Geneva, Switzerland
Deloria Knoll M:
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Green Submitted, Green Accepted, hybrid
|